The Bausch Lomb CEO resignation 2026 story is a leadership change at one of the world’s best-known eye health companies, announced with little explanation. On 12 October 2026, Bausch + Lomb said chief executive Brent Saunders is leaving, and that Thomas J. Appio, chief executive of parent company Bausch Health, has been named interim chief executive officer, effective immediately. The companies called the departure a mutual decision rather than a resignation.
The same announcement carried a financial signal: both companies expect to raise full-year 2026 adjusted EBITDA guidance. Here is what has been confirmed, what has not, and what to watch next.
Key facts on the Bausch Lomb CEO resignation 2026
- Who is leaving: Brent Saunders, who the announcement says has led Bausch + Lomb as chief executive since 2023.
- Who is stepping in: Thomas J. Appio, as interim CEO, effective immediately.
- Dual role: Appio keeps his job as chief executive of Bausch Health.
- Reason given: a mutual decision between Saunders and the board. No further explanation was disclosed, and the company declined further comment.
- Guidance: both companies expect to raise 2026 adjusted EBITDA guidance, excluding acquired in-process research and development, based on preliminary third-quarter results. No figures were given.
- Next date: third-quarter results are due on 28 October 2026.
Bausch Lomb CEO resignation 2026: what the announcement says
The release describes the change as a mutual agreement between Saunders and the board. Saunders said in his statement that the company is stronger, more focused and better positioned for the future. The board cited Appio’s knowledge of the business, his global leadership experience and his long connection to the company, and said these qualities position him to build momentum and lead the next phase of growth. Appio called the role a privilege and said the company is built on its people, its portfolio and its commitment to customers and patients. Those are the companies’ own words, and the announcement does not say how long the interim arrangement will last or whether a search for a permanent chief executive is under way.
Who is Thomas Appio, interim CEO after the Bausch Lomb CEO resignation 2026?
According to the announcement, Appio joined Bausch + Lomb in 2010 as managing director for China, became president of Bausch + Lomb International in 2016, and held other leadership roles before the company’s 2022 initial public offering. He has been chief executive of Bausch Health since 2022, and the companies say that business has grown revenue and adjusted EBITDA, excluding Bausch + Lomb, for 13 consecutive quarters under him. That is a company claim, and we have not verified the underlying figures.
One detail differs between sources. One account of the announcement says Appio has been chairman of the Bausch + Lomb board since August 2026, while another report does not mention a chairman role. We have treated the chairman role as reported by the company’s announcement but not independently confirmed, and the filing will settle it.
Brent Saunders and the Bausch Lomb CEO resignation 2026
Saunders is a familiar name in the industry. The announcement notes that he was previously chief executive of Bausch + Lomb from 2010 to 2013, until it was acquired by what was then Valeant Pharmaceuticals, now Bausch Health. His return as chief executive in 2023 therefore lasted roughly three years, by our count. The company has not given a reason for the departure, and in our assessment readers should avoid reading one into a mutual-decision announcement. The separation terms were not disclosed.
What the guidance signal means in the Bausch Lomb CEO resignation 2026
The companies said they are in a blackout period and expect, based on preliminary third-quarter results, to raise the full-year 2026 adjusted EBITDA outlook. A leadership change paired with an expected guidance raise is unusual, and it suggests the business is performing even as the top job changes hands. In our assessment, that combination is the company’s way of telling investors the change is not driven by weak trading. Without figures, though, the size of any raise is unknown until results on 28 October. Public coverage indicated that the share price fell on the news, but we could not confirm the size of the move from the material we reviewed.
Background to the Bausch Lomb CEO resignation 2026: the separation question
The change comes against an unresolved question about the relationship between the two companies. In December 2024, Bausch + Lomb said it was exploring a sale and other options toward a full separation from Bausch Health, and it later ended talks with a third-party buyer. One account of the timeline contains a date inconsistency, so we have not repeated the specific month. The announcement did not say whether the leadership change affects separation plans, and having one executive lead both companies on an interim basis may raise governance questions that the board has not addressed publicly.
What to watch after the Bausch Lomb CEO resignation 2026
- The company’s Form 8-K filing, which should give the formal terms of the change. Filings can be searched in the SEC’s EDGAR database.
- Whether a permanent chief executive search is announced and how long the interim period runs.
- The size of the 2026 guidance raise when third-quarter results arrive on 28 October.
- Any update on the separation from Bausch Health.
For other leadership and deal news in the sector, see our reports on the Stryker chief executive transition, the Viatris and Pacira acquisition, the STERIS and Xodus Medical deal and BD’s $19 billion US manufacturing plan, or browse more medical device news.
Frequently asked questions
Did Brent Saunders resign in the Bausch Lomb CEO resignation 2026?
The companies describe it as a mutual decision between Saunders and the board, not a resignation. No reason was disclosed.
Who is the interim CEO after the Bausch Lomb CEO resignation 2026?
Thomas J. Appio, who is also chief executive of Bausch Health, effective immediately.
Will guidance rise after the Bausch Lomb CEO resignation 2026?
The companies expect to raise full-year adjusted EBITDA guidance, based on preliminary third-quarter results. No figures were given.
When are Bausch + Lomb’s third-quarter results?
28 October 2026.
Is a permanent CEO being sought after the Bausch Lomb CEO resignation 2026?
The announcement does not say.
How we reported this: we relied on the companies’ announcement of 12 October 2026 and on coverage of the same statements. Claims about performance are the companies’. Figures and tenure estimates labelled as ours are our own. Last updated: 13 October 2026. This article is news reporting and not investment advice.